| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8922407 | Clinical and Translational Radiation Oncology | 2018 | 9 Pages |
Abstract
PATRIOT is a phase I study of the ATR inhibitor, AZD6738, as monotherapy, and in combination with palliative radiotherapy. Here, we describe the protocol for this study, which opened in 2014 and is currently recruiting and comprises dose escalation of both drug and radiotherapy, and expansion cohorts.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
M.T. Dillon, Z. Boylan, D. Smith, J. Guevara, K. Mohammed, C. Peckitt, M. Saunders, U. Banerji, G. Clack, S.A. Smith, J.F. Spicer, M.D. Forster, K.J. Harrington,